A Randomised, Open-label, Three-part, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 19 Jan 2018 Planned End Date changed from 29 Dec 2017 to 28 Dec 2018.
- 12 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 25 Mar 2016 Protocol amended as study design changed from single to parallel assignment as reported by ClinicalTrials.gov.